U bent hier: Home / Internationaal


Studenten die studeren aan de faculteit geneeskunde Kulak, kunnen tijdens hun opleiding een internationale ervaring opdoen.


Studenten geneeskunde kunnen in de derde fase kiezen om een studiereis naar de Filipijnen te maken


BMW studenten kunnen een week seminaries volgen in Lyon en seminaries volgen in het opleidingsonderdeel "internationalisation @home"



Filipijnen voor studenten Geneeskunde

Elk academiejaar krijgen studenten uit de opleiding geneeskunde de kans om een studiereis naar de Filipijnen te maken. 

Deze studiereis heeft tot doel de studenten reeds vroeg in de opleiding kennis te laten maken met hoe geneeskunde in een derde wereldland wordt uitgeoefend, om deze ervaring als mens, en toekomstig dokter, een leven lang mee te dragen. 

De studenten worden beoordeeld op hun medewerking tijdens de studiereis, schrijven een individueel verslag en organiseren een avond voor ouders, vrienden, de campusgemeenschap, ... om aan hen te tonen wat deze studiereis precies inhoudt.

Een voorsmaakje kan u hier bekijken 

Je kan de reis herlezen via deze blog (jaren 2006-2007-2008-2009-2010-2011- 2012 - 2013 - 2015)



Lyon voor studenten BMW

Voor de derde bachelor biomedische wetenschappen wordt een buitenlandse ervaring voorzien in de keuze-optie ‘internationalisering’ (5 SP). In de ‘Ecole Normale Supérieure’ van Lyon wordt jaarlijks een seminariereeks georganiseerd rond ‘virus and immunity’ en dit gedurende twee weken, waarvan een van deze twee weken bijna altijd in de eerste week van februari (lesvrije week) valt. Studenten van de derde fase BMW kunnen deze seminariereeks volgen.





Internationalisation @home

De studenten BMW kunnen ook een seminariereeks (5 SP) volgen aan Kulak, waarbij zes internationaal gerenommeerde
onderzoekers een seminarie van 3 uur zullen geven over hun biomedisch gericht onderzoek, verspreid over het academiejaar. Deze lessenreeks kan ook worden gevolgd door studenten van andere richtingen (Geneeskunde, W&T) en door doctoraatsstudenten. De studenten van Biomedische Wetenschappen die dit als keuzevak opnemen, volgen de 6 seminaries en maken een presentatie over één van de onderwerpen die ze verder uitgediept hebben.

Volgende onderwerpen komen aan bod:

Alle seminaries gaan door van 16u tot 19u in lokaal A305 tenzij hieronder anders aangegeven

Docent Titel en inhoud van de topic  

6 oktober 2016 - The life time of a scientific idea: from conception to written article

Dr. Laura Ravasi

Université de la droit et de la santé Lille 2, Lille, France

A good scientist is like a good cook, they need good ingredients and some know-how. In addition to having a good idea, there are some requirements to need to be met. The project has to be feasible, the method has to be validated or robust enough when first used, the written protocol has to be ethically approved. Financially and expertise-wise, the project needs to remain feasible or within reach. Regular meetings with all team-mates have to occur to explicit data analysis and interpret preliminary results. Finally, when the whole dish is ready, there is a need for hungry clients in the restaurant!

27 oktober 2016 - Data mining and data visualization in intensive care medicine

Dr. Fabian Güiza 

Laboratorium voor Intensieve Geneeskunde KU Leuven

Intensive care medicine allows patients to survive lethal insults through the use of monitoring systems, guiding medications and mechanical devices to support the function of vital organs. The Intensive Care Medicine Research Group of the KULeuven (LICM) combines a research laboratory with a large intensive care unit. As part of its mission to understand the mechanisms behind critical illness and to enhance recovery, the LICM has recently adopted data mining and data visualization approaches to study data from human critically ill patients and from animal models. In this seminar we will present our major findings when applying these novel techniques and their potential for improving management of the critically ill patient.

3 november 2016 - Blood cells, coagulation, and the development of antithrombotic drugs

Ian Del Conde

MD, Director of Vascular Medicine, Miami Cardiac and Vascular Institute
Baptist Hospital, Miami, Florida, United States                           

Thrombotic diseases account for the number one cause of death worldwide.  Not surprisingly, significant human and capital investments have been made over the past 50 years to understand the basic mechanisms of thrombosis and cardiovascular disease. The lecture will cover basic aspects of thrombosis, including interactions between blood cells and the vessel wall, and coagulation proteins.  We will discuss how some of the most important classes of antiplatelet drugs were developed and brought to the clinical arena, and will also review how market forces have determined the success and demise or certain antithrombotic therapies. Lastly, we will discuss evolving cardiovascular therapies, remaining challenges, and the drivers of innovation that that will determine how cardiovascular disease will be managed in the next 50 years.

10 november 2016 - Acute stroke: epidemiology, treatment and research

Dr. Tommy Andersson 

Neurosurgeon and Neuroradiologist, Karolinska university Hospital in Stockholm, Sweden and az  Groeninge in Kortrijk

Stroke is a huge health problem worldwide being the third most common cause of death and the most common reason for permanent disability in adults. In this lecture we will clarify what we mean with stroke, how it may be prevented and treated. Further, which new treatment possibilities that have recently emerged and where the forefront of stroke research is today. Afterwards the students should have gained insights into stroke definitions, epidemiology, treatment and research.

2 december 2016 - Translational Research in Neuromuscular Diseases - 14.30u - 17.30u - E 1001

Dr. Volker Straub

The John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle upon Tyne, UK

Genetic neuromuscular diseases (NMD) are a group of clinically and genetically heterogeneous diseases that are typically characterized by weakness and wasting of skeletal muscles. Many of the more than 500 different conditions show overlapping clinical features with acquired diseases of the peripheral nerves, the neuromuscular junction and the muscle. Although individually extremely rare, all types of NMD together are expected to affect about 1 in 3000 of the population. Despite improved diagnostics and pathomechanistic insight, effective therapies are currently lacking for the vast majority of these diseases.

Medical care consists of the symptomatic treatment of complications, aiming to improve life expectancy and quality of life. Besides well characterised pre-clinical tools like animal models and cell culture assays, the determinants of successful drug development programs for rare diseases include a good understanding of the phenotype and natural history of the disease, the existence of clinically relevant outcome measures, guidance on care standards, up to date patient registries, and, ideally, biomarkers that can help to assess disease severity or drug response. 

All these determinants constitute aspects of translational research efforts and influence patient access to therapies. The seminar will focus on the current status of determinants of successful drug development programs for NMD and the challenges of translating promising therapeutic strategies into effective and accessible treatments for patients.

23 maart 2017 - The human foot: how it evolved, how it works, and do we actually know? - E 1001

Dr. Kristiaan D’Août

University of Liverpool

The human foot has been considered “a marvellous piece of engineering” but at the same time, with 26 bones it seems highly redundant, and poses a substantial amount of “reliability” health issues in many people. In order to understand why the foot has the anatomy we know, we will first set out to explore how the foot evolved. Next, we will look at the function of the human foot during locomotion (walking and running). We will show how little we really know about how the human foot works, and why that is a problem. Finally, we will use the knowledge we do have, as well as very recent and on-going work, to try and answer questions such as “what is a normal human foot” and “do we need shoes at all”?


Meer praktische informatie over :